Efficacy and Safety of Vilazodone treatment for Major Depressive Disorder (MDD): A Pooled analysis of 3390 patients
Mohamed Ibrahim Gbreel 1, Mohammed Al-Kafarna2, Bashar Khaled Almaghary2, Hamdy Khaled Sabra3, Mustafa Adwan4, Osama Khalid Abdelgawad5, Fatma Elsheikh5, Ahmed Mahmoud Abdullah5, Hossam Waleed Almadhoon6, Esraa Abdelhameid Amer5, Ahmed Elsnhory5
1Faculty of Medicine, October 6 University, Giza, Egypt, 2Faculty of Pharmacy, Al-Azhar University - Gaza, Gaza Strip, Palestine, 3Faculty of Medicine, Tanta University, Tanta, Egypt, 4Faculty of Medicine, Al-Azhar University - Gaza, Gaza Strip, Palestine, 5Faculty of Medicine, Al-Azhar University, Cairo, Egypt, 6Faculty of Dentistry, Al-Azhar University - Gaza, Gaza Strip, Palestine
Objective:
In this study, we aim to investigate the efficacy and safety of Vilazodone treatment for relieving MDD symptoms upon valid scores.
Background:
Major depressive disorder (MDD) is a global health condition strongly related to both mental and physical consequences, functional impairment, and medical expenses. A wide range of antidepressant drugs could be prescribed for MDD patients; however, treatment discontinuation is always against disease control. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly effective MDD treatments and are prescribed as first-line antidepressants. Vilazodone treatment is one of the SSRI options for MDD.
Design/Methods:
Five databases were searched for literature search and seven included randomized clinical trials were finally meta-analyzed. We used the Review Manager software version 5.4.
Results:
The overall effect estimates significantly favored vilazodone and placebo groups favoring vilazodone regarding the Montgomery–Åsberg Depression Rating Scale (MADRS) (MD=−4.69, 95% CI:[−6.83, −2.55], P<0.0001), Clinical Global Impression (CGI) severity (MD=−0.29, 95% CI:[−0.41, −0.17], P<0.00001), and CGI improvement (MD=−0.36, 95% CI:[−0.44, −0.28], P<0.00001). The pooled analysis significantly favored Vilazodone regarding nausea, vomiting, diarrhea, somnolence, dry mouth, insomnia, and dizziness compared to controls.
Conclusions:
Vilazodone monotherapy is an effective well-tolerated, and safe drug for MDD patients in terms of multiple outcomes.